Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

The Latest on the Pfizer & Moderna COVID Vaccine Rollout

Stockhouse Editorial
2 Comments| September 24, 2021

{{labelSign}}  Favorites
{{errorMessage}}

There has been some movement on the COVID-19 vaccine front on Friday.

Pharmacy retail giant Walgreens (NASDAQ: WBA) announced that eligible people can now receive Pfizer COVID-19 booster vaccinations in stores nationwide, following Food and Drug Administration Emergency Use Authorization and new guidance from the Centers for Disease Control and Prevention (CDC).

While COVID-19 boosters are not widely available to the general population, the CDC recommends nearly everyone receive a flu shot to reduce illness and prevent flu-related hospitalizations and deaths.

Walgreens’ president, John Standley said that the chain has played a vital role in responding to COVID-19 as millions have turned to them as a convenient vaccination destination and critical point of community care.

“In addition to providing booster shots, our pharmacy teams remain readily available to advise patients, address questions and co-administer flu and COVID-19 primary vaccines to help protect our communities.”

For more details, click here.

Meanwhile, Moderna, Inc. (NASDAQ: MRNA) announced a supply agreement with the government of Peru for 20 million doses of Moderna’s COVID-19 vaccine to begin delivery in Q1 2022. The COVID-19 Vaccine Moderna is not currently approved for use in Peru, and the Company will work with regulators to pursue necessary approvals prior to distribution.

The biotechnology company is pioneering messenger RNA (mRNA) therapeutics and vaccines.



{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company